Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
Aileron Therapeutics Inc. (ALRN) is a clinical-stage biopharmaceutical company advancing novel therapies targeting p53 tumor suppression in oncology and orphan pulmonary diseases. This page serves as the definitive source for verified corporate announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on ALRN-6924's dual mdmx/mdm2 inhibition mechanism, pulmonary fibrosis candidate LTI-03, and other pipeline advancements. Our curated news collection includes earnings reports, partnership announcements, and scientific presentations - all essential for understanding the company's progress in stapled peptide therapeutics.
Content spans multiple categories including clinical trial milestones, FDA designations, financial disclosures, and peer-reviewed research publications. Bookmark this page for structured access to ALRN's evolving therapeutic pipeline and strategic business developments.
Aileron Therapeutics (Nasdaq: ALRN) announced that CEO Manuel Aivado will participate in a fireside chat at the William Blair Biotech Focus Conference 2022. The chat will be available on-demand starting July 11, 2022. Management will also meet in-person at the conference on July 12, 2022. Aileron focuses on chemoprotection oncology, aiming to make chemotherapy safer and more effective. Their lead product, ALRN-6924, is designed to protect healthy cells from chemotherapy while targeting cancer cells, particularly in patients with p53-mutated cancers, which encompass about 50% of cancer patients.
Aileron Therapeutics (ALRN) announced interim data from its Phase 1b trial focused on ALRN-6924 for NSCLC. Patients treated with ALRN-6924 completed 93% of the first four chemotherapy cycles compared to 78% on placebo, indicating a potential bias on the primary endpoint. The interim analysis showed 56% of cycles on ALRN-6924 were free of severe hematologic toxicities, compared to 50% for placebo. Aileron plans to halt further enrollment in the NSCLC trial and refocus on a Phase 1b breast cancer trial, applying insights from the NSCLC study to enhance the new protocol.
Aileron Therapeutics (Nasdaq: ALRN) has initiated a Phase 1b clinical trial for ALRN-6924, aimed at preventing chemotherapy-induced neutropenia and other toxicities in patients with p53-mutated breast cancer undergoing treatment with doxorubicin, cyclophosphamide, and docetaxel (AC+D). This regimen causes severe side effects, including neutropenia in 75% of patients. The trial will enroll 30 patients, with initial interim results expected in 4Q2022. Aileron highlights its innovative approach targeting p53-mutated cancers, which affects nearly 1 million U.S. patients annually.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) announced that CEO Manuel Aivado will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 1:30 p.m. ET in Miami, FL. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days thereafter.
Aileron focuses on chemoprotection in oncology, aiming to enhance chemotherapy safety and effectiveness. Their lead product, ALRN-6924, is a dual inhibitor designed to protect healthy cells from chemotherapy damage while targeting cancer cells.
Aileron Therapeutics (Nasdaq: ALRN) has announced a virtual KOL investor event scheduled for May 19, 2022, at 4:00 pm ET. The event will feature presentations from CEO Manuel Aivado and key opinion leaders, discussing the potential of ALRN-6924 as a precision medicine to mitigate chemotherapy-induced toxicities. Key topics include new data on ALRN-6924’s protective effects on hair follicles, updates on ongoing clinical trials for p53-mutated cancers, and planned data readouts for 2022. A live webcast will be available on the company's website.
Aileron Therapeutics (Nasdaq: ALRN) announced promising non-clinical findings regarding ALRN-6924, a dual inhibitor of MDM2/MDMX, which showed the potential to protect hair follicles from chemotherapy-induced damage. Specifically, ALRN-6924 was found to cause cell cycle arrest in human scalp hair follicles, which may prevent alopecia commonly associated with taxane-based chemotherapy like paclitaxel. Highlighted in a late-breaking presentation at the Society for Investigative Dermatology meeting, these results reinforce Aileron's strategy to enhance chemotherapy safety for patients with p53-mutated cancers.
Aileron Therapeutics (Nasdaq: ALRN) reported first-quarter 2022 results, with a net loss of $8.4 million, compared to $7.0 million in Q1 2021. The company has $38.1 million in cash, expected to fund operations into Q4 2023. Aileron is advancing its Phase 1b clinical trial of ALRN-6924 for advanced p53-mutated non-small cell lung cancer (NSCLC), with interim results anticipated in June 2022, and topline results projected for 4Q 2022. A second trial for p53-mutated ER+/HER2- breast cancer is set to begin in 2Q 2022. The company will host a virtual investor event on May 19, 2022.
Aileron Therapeutics (Nasdaq: ALRN) has appointed Christopher Zergebel as the new Vice President of Program Management and Clinical Operations, expanding its management team. With over 20 years of oncology experience, Zergebel aims to enhance operational excellence as Aileron develops ALRN-6924, a chemoprotective agent for p53-mutated cancers. The ongoing clinical trial for ALRN-6924 in non-small cell lung cancer is set to release interim data in June 2022, while enrollment for a breast cancer trial is anticipated in Q2 2022.
Aileron Therapeutics (Nasdaq: ALRN) reported its financial results for Q4 and the year ended December 31, 2021. The company aims to advance its chemoprotection strategy for patients with p53-mutated cancers, with several milestones expected in 2022, including interim data from Phase 1b trials for non-small cell lung cancer (NSCLC) and neoadjuvant breast cancer. As of December 31, 2021, Aileron had $45.9 million in cash, anticipated to fund operations through Q4 2023. However, the net loss for 2021 increased to $26.2 million, reflecting higher R&D expenses due to clinical activities.
Aileron Therapeutics (Nasdaq: ALRN) announced that CEO Manuel Aivado will present a company overview at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28th to 30th. Aileron focuses on developing chemoprotection therapies to enhance chemotherapy safety and efficacy. Their lead product, ALRN-6924, is a first-in-class dual inhibitor designed to activate p53, targeting patients with p53-mutated cancers. This innovative approach aims to protect healthy cells during chemotherapy, potentially improving patient quality of life and treatment tolerability.
